Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease

Neurology

Volumn 78, Issue 21, 2012, Pages 1650-1654

  Ondo, W G ^a   Kenney, C ^a   Sullivan, K ^b   Davidson, A ^c   Hunter, C ^c   Jahan, I ^b   McCombs, A ^b   Miller, A ^c   Zesiewicz, T A ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; CALCIUM CHANNEL BLOCKING AGENT; LUBIPROSTONE; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONSTIPATION; CONSTIPATION RATING SCALE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEMOGRAPHY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FECES ANALYSIS; FEMALE; FEVER; HALLUCINATION; HUMAN; INDIGESTION; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; UNIFIED PARKINSON DISEASE RATING SCALE; URINE INCONTINENCE; VISUAL ANALOG SCALE;

EID: 84863611367     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182574f28     Document Type: Article

References (33)

1. Parkinson J. An Essay on the Shaking Palsy. London: Whittingham and Roland; 1817.
2. Kaye J, Gage H, Kimber A, Storey L, Trend P. Excess burden of constipation in Parkinson's disease: A pilot study. Mov Disord 2006;21:1270-1273.
3. Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 2001;92:76-85.
4. Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007;22: 1623-1629.
5. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456-462.
6. Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Characterization of swallowing and defecation in Parkinson's disease. Am J Gastroenterol 1994;89:15-25.
7. Jost WH, Schimrigk K. Constipation in Parkinson's disease. Klin Wochenschr 1991;69:906-909.
8. Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time and rectoanal videomanometry in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:268-272.
9. Di Palma JA. Expert commentary: New developments in the treatment of constipation. Med Gen Med 2005;7:17.
10. Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991;6:151-156.
11. Bassotti G, Maggio D, Battaglia E, et al. Manometric investigation of anorectal function in early and late stage Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;68: 768-770.
12. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin-and substance P-containing neurons in Parkinson's disease. Brain Res 1990;510:104-107.
13. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134.
14. Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson's disease and megacolon: Concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987;37:1253-1255.
15. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: An immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 1990;79:581-583.
16. Singaram C, Ashraf W, Gaumnitz EA, et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995;346:861-864.
17. Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL. α-Synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: Autonomic pathway implicated in Parkinson's disease? Neuroscience 2008;153: 733-750.
18. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric α-Synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's diseaserelated brain pathology. Neurosci Lett 2006;396:67-72.
19. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45 (suppl 2):II43-II47.
20. Rivkin A, Chagan L. Lubiprostone: Chloride channel activator for chronic constipation. Clin Ther 2006;28:2008-2021.
21. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006;290:G942-G947.
22. Gage H, Kaye J, Kimber A, et al. Correlates of constipation in people with Parkinson's. Parkinsonism Relat Disord 2011;17:106-111.
23. Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson's disease: A randomized placebo-controlled study. Mov Disord 22: 1239-1244, 2007.
24. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson's disease: Objective assessment and response to psyllium. Mov Disord 1997;12:946-951.
25. Hamilton JW, Wagner J, Burdick BB, Bass P. Clinical evaluation of methylcellulose as a bulk laxative. Dig Dis Sci 1988;33:993-998.
26. Jost WH, Schimrigk K. Cisapride treatment of constipation in Parkinson's disease. Mov Disord 1993;8:339-343.
27. Jost WH, Schimrigk K. Long-term results with cisapride in Parkinson's disease. Mov Disord 1997;12:423-425.
28. Morgan JC, Sethi KD. Tegaserod in constipation associated with Parkinson disease. Clin Neuropharmacol 2007; 30:52-54.
29. Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov Disord 2006;21:115-116.
30. Sadjadpour K. Pyridostigmine bromide and constipation in Parkinson's disease. JAMA 1983;249:1148.
31. Albanese A, Brisinda G, Bentivoglio AR, Maria G. Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am J Gastroenterol 2003;98:1439-1440.
32. Albanese A, Maria G, Bentivoglio AR, Brisinda G, Cassetta E, Tonali P. Severe constipation in Parkinson's disease relieved by botulinum toxin. Mov Disord 1997;12:764-766.
33. Cadeddu F, Bentivoglio AR, Brandara F, Marniga G, Brisinda G, Maria G. Outlet type constipation in Parkinson's disease: Results of botulinum toxin treatment. Aliment Pharmacol Ther 2005;22:997-1003.